Cargando…
Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies
Previous commentaries in the Formulary Evaluation section of INNOVATIONS in Pharmacy have pointed to the lack of credibility in modeled claims for cost-effectiveness and associated recommendations for pricing by the Institute for Clinical and Economic Review (ICER). The principal objection to ICER r...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
University of Minnesota Libraries Publishing
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051888/ https://www.ncbi.nlm.nih.gov/pubmed/34007580 http://dx.doi.org/10.24926/iip.v10i4.2337 |